

INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES

Pharmaceutical Sciences

Research Article.....!!!

Received: 05-03-2012; Accepted: 11-03-2012

SIMULTANEOUS ESTIMATION OF OFLOXACIN AND CEFPODOXIME PROXETIL IN PHARMACEUTICAL DOSAGE FORM BY UV SPECTROPHOTOMETRIC METHOD

Dhaval R Chaudhari*, Rajesh R Parmar, Ashok N Mahajan, Dushyant A Shah

Department of Quality Assurance, APMC College of Pharmaceutical Education and Research, College Campus, Motipura, Himmatnagar – 383001, India

Keywords:

Ofloxacin,
Cefpodoximeproxetil, UV
Spectrophotometric,
Simultaneous equation

For Correspondence:

Dhaval R Chaudhari

Department of Quality
Assurance, APMC College
of Pharmaceutical
Education and Research,
College Campus, Motipura,
Himmatnagar – 383001,
India

E-mail:

dchaudhary1710@gmail.com

ABSTRACT

A simple, precise, accurate, rapid and economical spectrophotometric method have been developed for simultaneous estimation of Ofloxacin and Cefpodoxime proxetil in pure and in combined Tablet dosage form. Simultaneous equations method by using 293 nm and 263 nm as absorbance maxima (λ_{max}) for Ofloxacin and Cefpodoxime proxetil respectively. 0.1 M HCL as a Solvent. Linearity was observed in the concentration range of 2-10 $\mu\text{g/ml}$ for Ofloxacin and 2-10 $\mu\text{g/ml}$ for Cefpodoxime proxetil respectively. The method was validated statistically and recovery study was performed to confirm the accuracy of the method.

INTRODUCTION

Ofloxacin (OFLO) is chemically 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]1,4-benzoxazine-6-carboxylic acid[1] (Figure 1) is a fluoroquinolone antibacterial used in the treatment of chlamydia or chlamydophila infections including nongonococcal urethritis and in mycobacterial infections such as leprosy. It is official in IP, BP and USP. IP, BP and USP describe potentiometry method for its estimation.

Cefpodoximeproxetil (CEFPO) is chemically 1-(isopropoxycarbonyloxy) ethyl(6R,7R)-7-[2-(2-amino-4-thiazolyl)-(z)-2-(methoxyimino)acetamido]-3-methoxymethyl-3-cephem-4-carboxylate is a third generation cephalosporin antibiotic used for infections of the respiratory tract, urinary tract and skin and soft tissues. Cefpodoximeproxetil is official in IP and USP. IP and USP describe liquid chromatography method for its estimation.

A survey of literature revealed that few chromatographic and Spectrophotometric methods are reported for determination Ofloxacin and Cefpodoximeproxetil individually and with other drug combination. The present work describes simple, precise, accurate and economical spectrophotometric method have been developed for simultaneous estimation of Ofloxacin and Cefpodoximeproxetil from combined dosage form.

MATERIAL AND METHOD

Instrument

A Shimadzu model 1700 (Japan) double beam UV/Visible spectrophotometer with spectral width of 2 nm, wavelength accuracy of 0.5 nm and a pair of 10 mm matched quartz cell was used to measure absorbance of all the solutions.

Reagents and Chemicals

Reference Standards of Ofloxacin and Cefpodoxime Proxetil were obtained as gift samples from the Cadila Pharmaceutical Ltd and Montage lab pvt. The drug sample (Tablets) ZEDOCF - O by Macleods pharmaceutical ltd were procured from market. All other reagents were of analytical grade for Spectrophotometric method.

Procedures

Preparation of Standard Stock Solution and Calibration curve:

Standard stock solution of pure drug containing 1000 µg/ml of Ofloxacin and 1000 µg/ml of Cefpodoxime Proxetil were prepared in 0.1 M HCL and final volume was adjusted with same

solvent to get 1000 µg/ml of each drug. From the above solution prepare 100µg/ml solution for both drugs using 0.1 M HCL. Working standard solution of 10 µg/ml were scanned in the entire UV range 200-200nm to determine the λ max of both drug. The λ max of Ofloxacin and Cefpodoximeproxetil is 293 nm and 263 nm respectively. Five working standard solution with concentration 2,4,6,8,10µg/ml of Ofloxacin and 2,4,6,8,10µg/ml of Cefpodoxime proxetil. The absorbance of resulting solution were measured at their respective λ max and plotted a calibration curve to get linearity and regression equation.

Simultaneous Equation Method

The Simultaneous Equation Method of analysis based on the absorption of the drugs Ofloxacin and Cefpodoximeproxetil at their λ max. Two wavelength selected for the development of Simultaneous Equation are 293nm (λ_1) and 263nm (λ_2)absorptivities of both the drugs at both the wavelengths were determined.The equations obtained for the estimation of concentration were,

$$C_X = \frac{A_2 a_{Y1} - A_1 a_{Y2}}{a_{X2} a_{Y1} - a_{X1} a_{Y2}}$$

$$C_Y = \frac{A_1 a_{X2} - A_2 a_{X1}}{a_{X2} a_{Y1} - a_{X1} a_{Y2}}$$

Where A_1 and A_2 are absorbance of Sample solution at 293 and 263 nm respectively.

a_{X1} = Absorptivity of Ofloxacin at 293 nm

a_{X2} = Absorptivity of Ofloxacin at 263 nm

a_{Y1} = Absorptivity of Cefpodoximeproxetil at 293 nm

a_{Y2} = Absorptivity of Cefpodoximeproxetil at 263 nm

C_X and C_Y are concentration of Atorvastatin and Cefpodoximeproxetil in sample solution.

Procedure for Tablet formulation

Twenty Tablets were accurately weighed, and contents were removed. Average weight of the content per Tablet was calculated. The contents of a Tablet were reduced to fine powder. A quantity of Tablet powder equivalent to 200mg of Ofloxacin and 200mg of Cefpodoximeproxetil was transferred to 100ml volumetric flask and dissolved in 0.1 M HCL, sonicated for 20 min then filtered through Whatman filter. The Aliquot portion of filtrate was further diluted to get a final concentration of about 4µg/ml Ofloxacin and 4µg/ml of Cefpodoximeproxetil. For Simultaneous equation method. The absorbance of sample solution was measured at 293nm and 263nm in 1cm

cell against the blank. The content of Ofloxacin and Cefpodoximeproxetil in a Tablet was calculated by the simultaneous equation method.




Fig. 1: Chemical structure of ofloxacin




Fig. 2: Chemical structure of cefpodoxime proxetil (CEFPO)




Figure-3 Overlaid spectra of Ofloxacin (10µg/ml) and Cefpodoximeproxetil (10µg/ml)

Table-1 Optical Characteristic:

(Simultaneous equation method)				
Parameters	Ofloxacin		Cefpodoxime proxetil	
Wavelength	293	263	293	263
Beer's law limit	2-10	2-10	2-10	2-10
Regression equation	$y = 0.0885x + 0.0715$	$y = 0.0255x + 0.0022$	$y = 0.0224x - 0.078$	$y = 0.0373x - 0.0095$
Correlation coefficient (r^2)	0.998	0.998	0.998	0.998
LOD (µg /ml)	0.20	0.28	0.24	0.13
LOQ (µg /ml)	0.62	0.87	0.75	0.42

Table-2 Results of the recovery studies

Level of recovery %	Amount of pure drug added (µg/ml)		Simultaneous equation method % recovery	
	OFLX	CEFPODO	OFLX	CEFPODO
80	3.2	3.2	98.33	90.50
100	4	4	101.25	98.75
120	4.8	4.8	99.31	99.0
% recovery			99.9	99.0
%RSD			1.13	0.25

* RSD=Relative Standard deviation

Table-3 Results of analysis of Tablet formulation

Drugs	Simultaneous equation method
	%Assay \pm SD (n=6)
Ofloxacin (200mg)	100.25% \pm 0.95
Cefpodoxime proxetil (200mg)	98.25% \pm 0.45

Validation of the Method according to ICH Guidelines

Validation of the method was done according to ICH guidelines for Simultaneous Equation method.

Linearity

The linearity of the method is its ability to elicit test results that are directly proportional to the concentration of the analyte in the samples. OFLX was linear with the concentration range of 2-10 µg/ml at 293 nm. CEFPODO showed the linearity in the range of 2 – 10 µg/ml at 263nm.

Precision(repeatability)

The repeatability of the method was confirmed by the analysis of formulation was repeated for 6 times with the same concentration.

Intermediate precision(reproducibility):

The intraday and interday precision of the proposed method was determined by analyzing the corresponding responses 3 times on the same day and on 3 different days 3 different concentrations of standard solutions of OFLX and CEFPODO.

Accuracy (recovery study):

To check the accuracy of the proposed methods, recovery studies carried out at 80%, 100%, and 120% of the test concentration as per ICH Guideline. The recovery study was performed three times at each level.

Limit of detection and Limit of quantification:

The limit of detection (LOD) and the limit of quantification (LOQ) of the drug were derived by calculating the signal-to-noise ratio (S/N) using the following equations designated by International Conference on Harmonization (ICH) guidelines.

$$\text{LOD} = 3.3 \times \sigma/S, \text{LOQ} = 10 \times \sigma/S$$

Where, σ = the standard deviation of the response and S = slope of the calibration curve.

RESULTS AND DISCUSSION

In this method, two wavelengths were used for the analysis of the drugs. 293 nm (λ_{max} of OFLX) and 263 nm (λ_{max} of CEFPODO) are the wavelengths at which calibration curves were prepared for both the drugs. Linear correlation was obtained between absorbances and concentrations of OFLX and CEFPODO in the concentration ranges of 2-10 $\mu\text{g/ml}$ and 2-10 $\mu\text{g/ml}$ for both drugs respectively. The linearity of the calibration curve was validated by the high values of correlation coefficient of regression. LOD and LOQ values for OFLX were found to be 0.20 and 0.62 $\mu\text{g/ml}$ and 0.28 and 0.87 $\mu\text{g/ml}$ at 293 and 263 nm respectively. LOD and LOQ values for CEFPODO were found to be 0.24 and 0.75 $\mu\text{g/ml}$ and 0.13 and 0.42 $\mu\text{g/ml}$ at 293 and 263 nm respectively. These data show that method is sensitive for the determination of OFLX and CEFPODO. Both drugs showed good regression values at their respective wavelengths, and the results of a recovery study revealed that any small change in the drug concentration in the solution could be accurately determined by the proposed method. The proposed validated method was successfully applied to determine OFLX and CEFPODO in their combined dosage form. The results obtained for OFLX and CEFPODO were comparable with the corresponding labeled amounts (Table-3).

CONCLUSION

The proposed methods are simple, rapid and validated in terms of linearity, precision, accuracy, reproducibility, and can be used successfully for routine simultaneous estimation of Ofloxacin and Cefpodoximeproxetil in pure and Tablet dosage forms.

ACKNOWLEDGEMENT

The authors are thankful to Cadila Pharmaceutical Ltd,& Montage lab Pvt, Gujarat, India for providing gift sample of OFLX and CEFPODO for research. The authors are highly thankful to APMC College of Pharmaceutical education and research, Himatnagar, Gujarat, India for providing all the facilities to carry out the work.

REFERENCES

1. Maryadele, J. O' Neil. The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals, 14th edition. New Jersey, Published by Merck Research Laboratories, Division of Merck and Co., Inc. Whitehouse station, 2006;1170.
2. Sweetman SC, Eds. In The Martindale: The Complete Drug Reference, 35th edition. London, Pharmaceutical Press, 2007;277.
3. Indian Pharmacopeia, Vol. III. New Delhi, The Controller Publication, Govt. of India, 2010;1808.
4. British Pharmacopoeia, Vol. II. London, The British Pharmacopoeia Commission, 2010;1546.
5. The United State Pharmacopeia, USP28-NF23. Rockville MD: United State Pharmacopeial Convention, Inc, 2005;1416.
6. Juan GO, Lii QJ, Min D, Chaun DL. Recognition and simultaneous determination of ofloxacin enantiomers by synchronization - 1st derivative fluorescence spectroscopy. Talanta 2000;53:359-65.
7. Ballestros O, Luis VJ, Navalon A. Determination of the antibacterial ofloxacin in human urine and serum samples by solid-phase spectrofluorimetry. J Pharm Biomed Anal 2002;30:1103-10.
8. Wongsinsup C, Taesotikul W, Kaewvichit S, Sangsrijan S. Determination of ofloxacin in human plasma by HPLC with fluorescence detector. J Nat Sci 2009;8:165-74.
9. Basci N, Hanioglu K, Soysal H. Determination of ofloxacin in human aqueous humor by HPLC with fluorescence detection. J Pharm Biomed Anal 1997;15:663-66.
10. Francis, Paul, Adcock, Jacqui L. Chemiluminescence methods for the determination of ofloxacin. AnalyticaChimicaActa 2005;541:3-12.

11. Patel PU, Suhaghia BN, Patel MM, Patel GC, Patel GN. Spectrophotometric determination of ofloxacin with citric acid-acetic anhydride. *The Indian Pharmacist* 2007;6:59-61.
12. Puranik M, Bhawsar DV, Rathi P, Yeole PG. Simultaneous determination of ofloxacin and ornidazole in solid dosage form by RP-HPLC and HPTLC techniques. *Indian J Pharm Sci* 2010;72(4):513-17.
13. Maryadele, J. O' Neil. *The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals*, 14th edition. New Jersey, Published by Merck Research Laboratories, Division of Merck and Co., Inc. Whitehouse station, 2006;319.
14. Sweetman SC, Eds. *In The Martindale: The Complete Drug Reference*, 35th edition. London, Pharmaceutical Press, 2007;207.
15. *Indian Pharmacopeia*, Vol. III. New Delhi, The Controller Publication, Govt. of India, 2010;1018.
16. *The United State Pharmacopeia*, USP28-NF23. Rockville MD: United State Pharmacopeial Convention, Inc, 2005;397.
17. Darji BH, Shah NJ, Patel AT, Patel NM. Development and validation of a HPTLC method for the estimation of cefpodoximeproxetil. *Indian J Pharm Sci* 2007;69:331-33.
18. Singh S, Dubey N, Jain D, Tyagi L, Singh M. Spectrophotometric and RP-HPLC methods for simultaneous determination of cefpodoximeproxetil and clavulanate potassium in combined tablet dosage form, *American-Eurasian Journal of Scientific Research* 2010;5(2):88-93.
19. Gandhi S V, Patil U P, Patil N G. Simultaneous spectrophotometric determination of Cefpodoximeproxetil and Potassium clavulanate. *Hindustan Antibiot Bull* 2009;51(1-4):24-8.
20. *The International Conference on Harmonization, Q2 (R1), Validation of Analytical Procedure: Text and Methodology*, 2005.